Sat.Sep 25, 2021 - Fri.Oct 01, 2021

article thumbnail

Supporting Patient Adherence Through Electronic Prior Authorization and First Fill Copay Programs

Drug Channels

Today’s guest post comes from David Fidler, Senior Director of Product Innovation at ConnectiveRx. David discusses how electronic prior authorization (ePA) and first-fill, buy-down programs can boost patient adherence to specialty therapies. On November 3rd at 1:00 pm ET, ConnectiveRx will host First Fill, No Wait: How to Make it Happen , a free webinar about copay ePA.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Ukraine?

Drug Patent Watch

This chart shows the drugs with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

JAPAN’S MHLW APPROVES PFIZER’S CIBINQO® (ABROCITINIB) FOR ADULTS AND ADOLESCENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

The Pharma Data

Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO ® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies. CIBINQO will be available in Japan in doses of 100mg and 200mg.

article thumbnail

Latest news on drug repurposing in oncology #10

The Anticancer Fund

30 September 2021 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Drug Channels News Roundup, September 2021: Hospitals’ 340B Profits, Drug Prices Deflate, U.S. vs. EU, Amazon vs. CVS, and More Bad Blood for Theranos

Drug Channels

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 on international benchmarking goes viral Amazon is finally disrupting CVS—but not how you expected Plus, the best article ever about Elizabeth Holmes’s Theranos trial.

article thumbnail

Which pharmaceutical companies have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent…. The post Which pharmaceutical companies have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.

More Trending

article thumbnail

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN

The Pharma Data

Extension analyses observed patients taking AJOVY experienced a reduction in migraine and headache days and evaluated disability and health-related quality of life. Online symposium to highlight healthcare and neurology disparities as a major public health issue and discuss the state of diversity in migraine clinical studies, barriers to recruitment, and the need for more inclusive and diverse studies.

article thumbnail

World Rabies Day: Boehringer Ingelheim fights rabies misconceptions

The Pharma Data

Boehringer Ingelheim again joins efforts to fight rabies under this year’s theme for World Rabies Day by GARC: “Rabies: Facts, not Fear” Boehringer Ingelheim strives to raise awareness of the disease and its preventio. Today on World Rabies Day, we commemorate the death of Pasteur who developed the primary rabies vaccine, laying the foundations for rabies prevention.

Vaccine 52
article thumbnail

Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options

The Pharma Data

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S. retail pharmacies Monthly prescriptions for all Lilly insulins — including Insulin Lispro Injection — remain available for $35 through the Lilly Insulin Value Progra

article thumbnail

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

The Pharma Data

Results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials show that response rates for deucravacitinib continued to extend through Week 24 and were maintained through Week 52 in patients with moderate to severe plaque psoriasis. Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies.

Disease 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

New patent for Pf Prism drug BOSULIF

Drug Patent Watch

Annual Drug Patent Expirations for BOSULIF Bosulif is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are four…. The post New patent for Pf Prism drug BOSULIF appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Bulgaria?

Drug Patent Watch

This chart shows the drugs with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

FDA authorizes software that can help identify prostate cancer

The Pharma Data

Today, the U.S. Food and Drug Administration authorized marketing of software to help medical professionals who examine body tissues (pathologists) within the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue faraway from the body). The software, called Paige Prostate, is that the first AI (AI)-based software designed to spot a neighborhood of interest on the prostate biopsy image with the v

FDA 52
article thumbnail

University of Oxford and Oracle Cloud System helping researchers identify COVID-19 variants faster

The Pharma Data

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford Unive

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection

The Pharma Data

Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza New research from Sanofi Pasteur on respiratory syncytial virus (RSV), meningococcal disease, and influenza are going to be featured at IDWeek 2021, from Michaelmas to October 3, 2021, underscoring the company’s pledge to develop meaningful solutions for patients.

Vaccine 52
article thumbnail

Blood vessels produce protein that promotes metastases

The Pharma Data

Blood vessels supply tumors with nutrients and, on the opposite hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells during a distant organ is promoted by factors whose production is induced by the first tumor itself. Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically

article thumbnail

Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population

The Pharma Data

An expert review by a world group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the overall population aren’t appropriate at this stage within the pandemic. The review, published within the Lancet, summarises the currently available evidence from randomised controlled trials and observational studies published in peer-reviewed journals and pre-print servers.

Vaccine 52
article thumbnail

How a plant virus could protect and save your lungs from metastatic cancer

The Pharma Data

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a replacement treatment that would keep metastatic cancers cornered from the lungs. The treatment not only slowed tumor growth within the lungs of mice with either metastatic carcinoma or melanoma, it also prevented or drastically minimized the spread of those cancers to the lungs of healthy mice that were challenged with the disease.

Virus 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

COVID-19 nasal vaccine candidate effective at preventing disease transmission

The Pharma Data

Breathe in, exhale. That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in developing intramuscular vaccines against SARS-CoV- 2, like the readily available Pfizer, Moderna and Johnson & Johnson vaccines, nothing yet – sort of a nasal vaccine – has been approved to supply mucosal immunity within the nose, the primary barrier against the virus before it travels right down to the lungs.

Vaccine 52
article thumbnail

Which pharmaceutical companies have the most aerosol dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most aerosol dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most aerosol dosed drugs…. The post Which pharmaceutical companies have the most aerosol dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for Veloxis Pharms drug ENVARSUS XR

Drug Patent Watch

Annual Drug Patent Expirations for ENVARSUS+XR Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Veloxis Pharms drug ENVARSUS XR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Secura drug FARYDAK

Drug Patent Watch

Annual Drug Patent Expirations for FARYDAK Farydak is a drug marketed by Secura and is included in one NDA. It is available from one supplier. There are five patents protecting…. The post New patent expiration for Secura drug FARYDAK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Bayer Middle East announces partnership with the United Nations Population Fund Egypt, to support the Ministry of Health and Population’s ‘Your Right to Plan’ campaign in Egypt on World Contraception Day

The Pharma Data

The ‘Your Right to Plan’ campaign aims at improving family planning and reproductive health services to Egypt’s underserved communities / The five-year partnership involves a total donation of EUR 330,000 / The program provides access to medical services in relation to family planning, such as OB-GYN examinations, ultrasound diagnosis, and pediatric services.

Science 52
article thumbnail

Bayer to spotlight expanded research from growing oncology portfolio at ESMO Congress 2021

The Pharma Data

Updated analyses for Vitrakvi (larotrectinib) reaffirm sustained clinical benefits for patients with TRK fusion cancer / Breadth of prostatic adenocarcinoma portfolio on display, including presentations for Nubeqa (darolutamide) in non-metastatic castration-resistant prostatic adenocarcinoma (nmCRPC), and Xofigo (radium-223 dichloride) in metastatic castration-resistant prostatic adenocarcinoma (mCRPC) / public speaking on analysis from CHRONOS-3 study evaluating Aliqopa (copanlisib) plus rituxi

article thumbnail

Andes raises USD 15 million in Series A funding co-led by Leaps by Bayer and Cavallo Ventures

The Pharma Data

Andes has developed novel seed treatment technology that allows crops to thrive without synthetic fertilizers / Funds will aid the development of revolutionary nature-based carbon capture technology. Leaps by Bayer, the impact investment arm of Bayer AG, today announced that it has co-led a USD 15 million Series A investment round in agriculture and biotechnology innovator, Andes , with Cavallo Ventures.

article thumbnail

Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer

The Pharma Data

In an updated analysis on the adult subset of non-central systema nervosum (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high overall response rate (ORR) of 67% with a median duration of response (mDoR) of 49.3 months was observed also as an extended progression-free survival (PFS; median of 25.8 months) as assessed by investigators / post hoc ergo propter hoc sub-analysis of investigator-assessed ORR, DoR and PFS of patients (n=218) show uniformly high ORRs in p

article thumbnail

Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease

The Pharma Data

There are limited treatment options available for chronic renal disorder (CKD), and patients often still reach renal failure or premature death / The phase III clinical trial study FIND-CKD will investigate the effect of finerenone on kidney and cardiovascular outcomes in patients with non-diabetic chronic renal disorder Bayer announced today the initiation of the FIND-CKD study, a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial study to research the efficacy a

article thumbnail

New phase III clinical trial data support the advantage of Roche’s Tecentriq in early-stage carcinoma

The Pharma Data

Roche today presented new data from the phase III clinical trial IMpower010 study at the ecu Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the many disease-free survival (DFS) benefit offered by Tecentriq® (atezolizumab) for people with Stage II-IIIA non-small cell carcinoma (NSCLC) whose tumours express PD-L1?

article thumbnail

Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients

The Pharma Data

Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised. 1-3 Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample.

article thumbnail

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders

The Pharma Data

New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the power to swallow Evrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries worldwide Further presentations included data from studies supporting the efficacy, safety, and sturdiness of gene therapy, SRP-9001, within the treatment of Duchenne dystrophy (DMD).

article thumbnail

FDA In Brief: FDA Announces Public Workshop to Reconsider Mandatory Prescriber Education for Opioids

The Pharma Data

The following quote is attributed to Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research. “The opioid crisis continues to evolve and there are still relevant concerns with overprescribing, especially among vulnerable populations. Although many public and personal entities have independently implemented their own education schemes and other interventions to encourage safe and effective prescribing practices for opioid analgesics, there’s no consistent edu

FDA 52
article thumbnail

FDA In Brief: As Consumers Order More Meals and Groceries Online, FDA Plans Public Meeting to deal with Food Safety Risks

The Pharma Data

The following quote is attributed to Frank Yiannas, Deputy Commissioner for Food Policy and Response. “The COVID-19 pandemic has accelerated the necessity for the FDA to assist make sure that foods ordered online and delivered on to consumers are safe to eat and not in danger of contamination. We said within the New Era of Smarter Food Safety blueprint that we might hold a summit to deal with the potential safety vulnerabilities of those foods, especially during the critical “last mile” of deliv

FDA 52
article thumbnail

FDA Will Follow The Science On COVID-19 Vaccines For Young Children

The Pharma Data

As schools round the country are re-opening for in-person learning and families are returning to their busy academic year schedules, we all know many parents are anxious about the pandemic and protecting their children. Many parents have questions on COVID-19 and when vaccines are going to be available for youngsters younger than 12 years aged. Many of our team at the FDA are parents and grandparents themselves, and our team shares an equivalent concerns as many in our country about protecting o

Vaccine 52